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bjectives The multicenter AUTAX (Austrian Multivessel TAXUS-Stent) registry investigated the 2-year
linical/angiographic outcomes of patients with multivessel coronary artery disease after implantation of
AXUS Express stents (Boston Scientiﬁc, Natick, Massachusetts), in a “real-world” setting.
ackground The AUTAX registry included patients with 2- or 3-vessel disease, with/without previ-
us percutaneous coronary intervention (PCI) and concomitant surgery.
ethods Patients (n  441, 64  12 years, 78% men) (n  1,080 lesions) with possible complete
evascularization by PCI were prospectively included. Median clinical follow-up was 753 (quartiles
28 to 775) days after PCI in 95.7%, with control angiography of 78% at 6 months. The primary end
oint was the composite of major adverse cardiac (nonfatal acute myocardial infarction [AMI], all-
ause mortality, target lesion revascularization [TLR]) and cerebrovascular events (MACCE). Potential
isk factor effects on 2-year MACCE were evaluated using Cox regression.
esults Complete revascularization was successful in 90.5%, with left main PCI of 6.8%. Rates of acute,
ubacute, and late stent thrombosis were 0.7%, 0.5%, and 0.5%. Two-year follow-up identiﬁed AMI
1.4%), death (3.6%), stroke (0.2%), and TLR (13.1%), for a composite MACCE of 18.3%. The binary reste-
osis rate was 10.8%. The median of cumulative SYNTAX score was 23.0 (range 12.0 to 56.5). The SYNTAX
core did not predict TLR or MACCE, due to lack of scoring of restenotic or bypass stenoses (29.8%). Age
hazard ratio [HR]: 1.03, p  0.019) and acute coronary syndrome (HR: 2.1, p  0.001) were signiﬁcant
redictors of 2-year MACCE. Incomplete revascularization predicted death or AMI (HR: 3.84, p  0.002).
onclusions With the aim of complete revascularization, TAXUS stent implantations can be safe for pa-
ients with multivessel disease. The AUTAX registry including patients with post-PCI lesions provides ad-
itional information to the SYNTAX (Synergy Between Percutaneous Coronary Intervention With TAXUS
nd Cardiac Surgery) study. (Austrian Multivessel TAXUS-Stent Registry; NCT00738686) (J Am Coll
ardiol Intv 2009;2:718–27) © 2009 by the American College of Cardiology Foundation
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719he introduction of drug-eluting stents (DES) in recent
ears demonstrating superiority over bare-metal stents in
educing the restenosis incidence has narrowed the reinter-
ention gap between coronary artery bypass graft surgery
CABG) and percutaneous coronary intervention (PCI) in
ultivessel coronary artery disease (CAD) (1–7); multives-
el stenting with DES has therefore moved into the fore-
round again as an alternative option for CABG.
See page 728
The high revascularization rate with DES compared with
ABG remains a critical end point in multivessel CAD
8,9). However, given the approximate 7% frequency of
n-hospital vein graft occlusion (10,11) and the degenera-
ion of vein grafts over time, DES may still be a more
urable means than CABG as a revascularization strategy.
nterestingly, even if stenting of multiple lesions is classified
s an “off-label” indication for DES, approximately 10% of
ll PCIs in Europe and the U.S. are performed in patients
ith multivessel CAD.
Although current randomized trials involving the com-
arison of DES and CABG in multivessel CAD have
ncouraged inclusion of a wide variety of lesion sets, data
uggest a significant variation in anatomical complexity
etween PCI and CABG patients (12,13). In the study by
offman et al. (1), only 2% to 12% of the patients screened
ould be randomized to either PCI or CABG (1). The goal
f the SYNTAX (Synergy Between Percutaneous Coronary
ntervention With TAXUS and Cardiac Surgery) trial, with
andomized and registry cohorts, was to provide guidance
n optimal revascularization strategies for patients with
igh-risk stenosis (12,14). However, the trial included only
atients with de novo lesions, whereas the rapid increase in
CI in the last 10 years has led to turn the anatomy of the
oronary lesions to present more complex morphology,
nvolving restenosis, aneurysms, vessel remodeling, and
henotypic modulation of intima post-stenting (15). Ac-
ordingly, registries of nonrandomized patients with subop-
imal lesions (e.g., restenotic stented lesions; or occluded,
alcified, bypass; or small vessels) for either revascularization
trategy may provide revascularization outcome data as
obust as those from randomized analyses (13).
The aim of the AUTAX (Austrian Multivessel TAXUS-
tent) registry was to conduct a multicenter prospective registry
ncluding patients with multivessel CAD with/without previ-
us PCI or concomitant cardiac surgery with possible complete
evascularization by PCI, and treated solely with multiple
AXUS Express stent (Boston Scientific, Natick, Massachu-
etts) implantations in a “real-world” setting, and to report the
hort (30 days), medium (6 months), and long-term (1 and 2
ears) angiographic and clinical outcomes. ethods
tudy design. The prospective academic nonrandomized
UTAX registry included consecutive patients with mul-
ivessel CAD at 9 Austrian medium- and high-volume PCI
enters.
tudy population. Between June 2004 and September 2005,
41 consecutive (all incoming) patients (age 64.4  11.8
ears, 78% men) with symptomatic multivessel CAD and
ossible percutaneous complete anatomical revasculariza-
ion were prospectively included in the registry. Assignment
o multivessel PCI with DES, rather than to CABG, was
ade on the basis of the individual clinical assessments by
ardiologists and cardiac surgeons, involving a spectrum
f factors such as extent and
natomy of CAD, the feasibility
f achieving complete revascu-
arization, age, prior surgery,
urrent cardiac function, co-
orbidities, general health,
ulmonary function, risk of an-
icoagulation, likelihood of com-
liance with continuing clopi-
ogrel therapy, urgency of
evascularization, assumption of
isk of percutaneous procedure,
nd the waiting period for
ABG in nonurgent cases. The
ultidisciplinary team, which
lso included noninvasive cardi-
logists, ensured that the most
alanced and appropriate advice
as consistently offered regard-
ng the choice of revasculariza-
ion strategy.
The study protocol con-
ormed to the Declaration of
elsinki and was approved by
he Interventional Working
roup of Austrian Society of
ardiology and the institutional
eview committees of all centers. All patients gave their
ritten informed consent and received optimal medical
herapy according to current guidelines.
The inclusion criteria were symptomatic 2- or 3-vessel
isease with/without left main disease, age18 years, stable
ngina, or acute coronary syndrome (unstable angina and
on–ST-segment elevation myocardial infarction [UA/
STEMI]). Exclusion criteria were ST-segment elevation
yocardial infarction within 48 h, cardiogenic shock, non-
ompliance with the study protocol, expected survival less
han 2 years, hemorrhagic diathesis, and/or platelet count
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CABG  coronary artery
bypass graft surgery
CAD  coronary artery
disease
CI  confidence interval
CK  creatine kinase
DES  drug-eluting stent(s)
HR  hazard ratio
MACCE  major adverse
cardiac and cerebrovascular
event(s)
MLD  minimal lumen
diameter
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary intervention
TLR  target lesion
revascularization
UA  unstable angina100,000/ml3.
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720tudy end points. The primary end point of the registry was
he incidence of major adverse cardiac and cerebrovascular
vents (MACCE), defined as all-cause death, nonfatal acute
yocardial infarction (AMI), target lesion revascularization
TLR), and cerebrovascular event during the 2-year clinical
ollow-up.
The secondary end points of the study included the: 1)
reak down primary end points at the 2-year (2 months)
ollow-up, such as the rate of TLR, nonfatal AMI, all-cause
eath, stroke, and the composite of death or AMI; 2) the
0-day, 6-month, and 1-year MACCE; 3) the acute,
ubacute, and late thrombosis rates; and 4) the angiographic
nd points such as the binary restenosis rate per lesion
defined as diameters stenosis 50%), in-stent, and proxi-
al and distal in-lesion late lumen loss.
tenting procedure and follow-up. Pre- and post-stent dila-
ions were performed at the interventionist’s discretion. Load-
ng doses of 300 to 600 mg clopidogrel and 250 mg aspirin
ere administered either before the procedure (at least 6 h
efore stenting in 91% of patients) or immediately after
iagnostic coronary angiography before the start of PCI.
uring the 2-year follow-up, patients were treated with a
5-mg daily dose of clopidogrel and 100 mg aspirin.
With regard to clinical considerations arising from mul-
ivessel stenting, all patients were requested to return to
ngiographic follow-up at 6  1 months after PCI. The
atients were controlled clinically 30  7 days, 1  0.2
ears, and 2  0.3 years after PCI.
uantitative coronary angiography. Pre-, post-stenting,
nd follow-up minimal lumen diameters (MLDs), reference
egment diameters, and percentage diameter stenosis were
etermined by using a quantitative angiography program
ACOMPC, Siemens, Munich, Germany). Acute lumen
ain (post- minus pre-angioplastic MLD) and late lumen
oss (post-stent MLD minus follow-up MLD) were calcu-
ated. Quantitative analysis was performed in the “in-stent”
rea (“in-stent” analysis) and in the proximal and distal
in-lesion” area, including the stented segment and also the
-mm margins both proximal and distal to the DES. Binary
ngiographic restenosis was defined as stenosis of at least
0% of the MLD in the target lesion at follow-up angiog-
aphy. SYNTAX score was calculated (16) for all lesions
ntended to be treated with PCI.
eﬁnitions. Two-vessel disease was defined as disease in 2
f the 3 major epicardial vessels, and 3-vessel disease as
isease in all 3 vessels. Complete revascularization was
efined as restoration of Thrombosis In Myocardial Infarc-
ion (TIMI) flow grade 3 with residual stenosis 30% to all
yocardial territories. Complex lesions were defined as type
2 or C according to a modified American College of
ardiology/American Heart Association classification.
The off-label use of stents was defined if the indication of
ES implantation did not meet the standard criteria (e.g.,estenotic lesion; lesion in a bypass graft; a lesion length S30 mm or reference vessel diameter 2.5 mm or 3.75
m; or ostial, bifurcated, or totally occluded lesions).
The procedural success of PCI was stated as TIMI flow
rade 3, with a final residual stenosis of 30% without
eath, myocardial infarction, or emergency CABG before
ospital discharge.
TLR was recorded as repeated revascularization for ste-
osis of at least 50% of the luminal diameter anywhere
ithin the stent or within the 5-mm borders proximal or
istal to the stent. Myocardial infarction was defined as
ither Q-wave (significant new Q waves in at least 2
lectrocardiographic leads as compared with the pre-
reatment electrocardiogram, and chest discomfort associ-
ted with creatine kinase [CK] elevation 3 the upper
imit of the normal value) or non–Q-wave myocardial
nfarction (elevation of CK levels 2 the upper limit of
ormal with positive CK-MB or elevation of CK levels to
2 upper limit of normal without new Q waves). The
ame myocardial infarction definition was used for the entire
ollow-up. Death was defined as any post-procedural death
nd was considered of cardiac origin unless there was
ocumentation of another cause.
Cerebrovascular events were defined as stroke, transient
schemic attacks, and reversible ischemic neurologic deficits
asting more than 24 h, diagnosed by a neurologist, and
onfirmed by imaging modalities. In cases of multiple events
ccurring in 1 patient, the first event was entered into the
nalysis.
Acute, subacute, and late stent thrombosis were defined
ithin 24 h, within 1 month after stent implantation, or
fter 1 month, respectively, in accordance with the Aca-
emic Research Consortium definitions (17).
Major bleeding was determined as clinically significant
emorrhage of any location, or with hemoglobin decrease
4 g/dl, overt bleeding with hemoglobin decrease 3 g/dl,
r transfusion of 2 U of blood.
tatistics. Angiographic and clinical outcomes were analyzed
ccording to intention to treat. Descriptive statistical analysis
as performed by using continuous variables expressed as
ean value  standard deviation (for parameters with normal
istribution) or median with interquartile ranges (for parame-
ers with skewed distribution) and by using categorical vari-
bles presented as percent frequency. For comparison between
roups of the pre-specified subanalysis, 2-tailed t tests were
sed for the continuous variables.
Univariate and multiple Cox regression models were
sed to evaluate the effects of potential risk factors on
vent-free (MACCE-free) survival. The following vari-
bles were considered in the univariate and multiple
egression models: age, sex, diabetes, hypercholesterol-
mia, 3-vessel disease, previous PCI/CABG, incomplete
evascularization, UA/NSTEMI, total stent length, and
YNTAX score (both log-transformed values due to
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721kewed distribution). Additionally, a stepwise Cox regres-
ion analysis (forward selection method) was performed,
ncluding only statistically significant prognostic factors in
he multiple regression model. The estimated relative risks
ith 95% confidence intervals (CIs) were calculated.
The 2-year cumulative incidence rates of individual clin-
cal outcomes and composite outcomes were compared in
ubgroups of patients at high risk of having at least 1 of the
ndependent predictors. Kaplan-Meier estimates (supple-
ented by log-rank statistics) were used to plot the rates of
omposite MACCE and death or AMI. Mortality assess-
ent included in-hospital deaths.
Univariate logistic regression analysis was performed to
valuate the influence of chronic total occlusion on incom-
lete revascularization. The strength of this potential influ-
nce is described by the odds ratio (with 95% CI).
Receiver-operator characteristic analysis was performed
o determine a potential cutoff point of SYNTAX score for
rediction of TLR and MACCE at 2-year follow-up, with
calculation of predictive accuracy. Patients lost to
ollow-up (n  19) or with a 2  0.3-year follow-up
ithout events were excluded from this analysis.
All clinical data were recorded in the angiographic core
aboratory of the Medical University of Vienna. The quan-
itative angiography was analyzed by an independent expert,
ot involved in the trial. The statistical analysis was per-
ormed by an independent statistician. Statistical analysis
as carried out using the SPSS (version 17.0, SPSS Inc.,
hicago, Illinois) and SAS (version 9.2, SAS Inc., Cary,
orth Carolina) programs in accordance with the previously
et plan of the protocol. A p value of 0.05 was considered
Table 1. Number of Patients With Multivessel CAD and
Treatment Options
Screened patients 1,012
CABG 473
Complex anatomy 353 (74.6%)
Chronic total occlusion untreatable with PCI 78 (16.5%)
Dual antiplatelet therapy is not possible, or
patient incompliance
26 (5.5%)
Patient refused PCI 3 (0.7%)
Others 13 (2.7%)
PCI 542
Included in the AUTAX registry 441
Comorbidities 208 (47.2%)
No. of graft vessel 24 (5.4%)
Poor distal vessel quality 48 (10.9%)
Patient refused CABG 131 (29.7%)
Others 30 (6.8%)
Not included in the AUTAX registry (met exclusion criteria) 101
AUTAX  Austrian Multivessel TAXUS-Stent; CABG  coronary artery bypass surgery; CAD 
coronary artery disease; PCI percutaneous coronary intervention.o be statistically significant.esults
total of 1,012 patients with multivessel CAD were
creened; 473 patients underwent CABG and 542 PCI; 101
atients with PCI met exclusion criteria, and were therefore
ot included in the registry (Table 1).
evascularization and baseline clinical characteristics. A to-
al of 1,080 lesions (2.45  0.31 lesions/patient) were
reated solely with TAXUS stents (n  1,401, 3.18  0.24
tents/patient). The procedural success rates were 100%,
8.9%, and 97.1% for the first, second, and third vessels,
espectively. Table 2 presents the prevalence rates of risk
actors. The lesion and procedural characteristics are listed
n Table 3 and Figure 1. Table 3 presents the off-label
ndications (beyond the multivessel CAD) for lesions.
Pre-dilation was performed in 24.8%, 21.0%, and 37.9%
f the first, second, and third lesions, respectively, and
ost-dilation in 26.8%, 25.3%, and 14.5% of the first,
econd, and third lesions, respectively.
Complete revascularization could be achieved in 90.5% of
atients. The reason for the lack of complete revasculariza-
ion was procedural complication (3.6% due to side-branch
cclusion, vessel dissection, and/or closure), a nonsatisfac-
ory result of PCI (0.4% of patients), or nontreatment of a
ignificant lesion for any reason (5.5% due to the discovery
f poor anatomical situation of the lesion during PCI). The
cute lumen gain was 1.54  0.48 mm in all lesions. Pre-
nd post-stenting and follow-up angiographic results are
hown in Table 4.
Table 2. Baseline Patient Characteristics
Age (yrs) 64.4 11.8
Men 344 (78.0%)
Diabetes mellitus 140 (31.7%)
Hypertension 358 (81.2%)
Hyperlipidemia 329 (74.6%)
Current smoker 148 (33.6%)
Family history of coronary artery disease 116 (26.3%)
Previous AMI 116 (26.3%)
Previous CABG 13 (3.0%)
Previous PCI 171 (38.8%)
Restenosis 1 lesion 118 (26.8%)
CK pre-PCI (U/l) 206 471
CK post-PCI (U/l) 196 447
Indication for PCI
Stable angina 296 (65.1%)
CK pre-PCI (U/l) 81 38
CK post-PCI (U/l) 114 171
UA/NSTEMI 145 (34.9%)
CK pre-PCI (U/l) 679 882
CK post-PCI (U/l) 632 942
AMI acutemyocardial infarction; CK creatine kinase; UA/NSTEMIunstable angina/non–ST-segment myocardial infarction; other abbreviations as in Table 1.
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722rimary end point. Tables 5 and 6 report the adverse event
ates during the follow-ups. The cumulative MACCE
robabilities were estimated by the Kaplan-Meier method.
ineteen patients (4.3%) were controlled at 6 months, but
hen lost to follow-up. The national mortality registry did
ot record death in any of the lost-to-follow-up patients.
ontrol angiography (routine or clinically driven) was per-
ormed in 344 patients (78%) (832 of 1,080 lesions, 77%)
.5  2.8 months after the index procedure.
During the overall study period, 78 patients suffered from
ACCE, which was mainly because of TLR (n  60).
ixteen of 60 patients underwent TLR of 1 lesion, and 11
Table 3. Procedural Characteristics
Procedural characteristics in patients (n  441)
Total SYNTAX score 23 (19.0 to 29.0)
Total Parsonnet score 8.1 6.5
Additive EuroScore 3.6 2.8
Lesion treated/patient 2.45 0.31
Number of stent implanted (/patient) 3.18 0.24
Total stent length per patient (mm) 62.2 25.7
Lesion in left main coronary artery 30 (6.8%)
Left main with 1-vessel disease 5 (1.1%)
Left main with 2-vessel disease 1 (0.2%)
Left main with 3-vessel disease 24 (5.4%)
2-vessel disease without left main lesion 274 (62.1%)
3-vessel disease without left main lesion 161 (36.5%)
Lesions in proximal left anterior descending coronary
artery
175 (39.7%)
Ostial lesion (left and/or right) 45 (10.2%)
Bifurcation lesion 84 (19.0%)
Chronic total occlusion 67 (15.2%)
Diffuse disease or small vessel 144 (32.7%)
Lesion length 100 mm 156 (35.4%)
No. of patients with 1 lesion for off-label indication 354 (80.1%)
No. of patients with 2 lesions for off-label indication 257 (59.3%)
Complete revascularization 399 (90.5%)
Hospital stay (days) 3.3 1.8
Lesion characteristics (n  1,080)
Total number of lesions 1,080
Number of implanted stents 1,401
Stent/lesion ratio 1.3 0.2
Lesion length 19.9 12.6
Stent length/lesion (mm) 25.8 9.7
Stent size (mm) 2.9 0.4
Stent implantation pressure (atm) 14.1 2.9
Reference vessel diameter 2.5 mm (per lesion) 334 (30.9%)
Reference vessel diameter 3.75 mm (per lesion) 25 (2.31%)
ACC/AHA classiﬁcation (in 1,080 lesions)
A 127 (11.8%)
B1 424 (39.3%)
B2 335 (31.0%)
C 194 (17.9%)
ACC/AHA American College of Cardiology/American Heart Association.atients repeated TLR during the 2-year follow-up.No differences between 2- or 3-vessel disease with/
ithout left main lesion were recorded regarding the 2-year
ACCE, or the breakdown primary end point events. A
rend towards higher MACCE rate was documented for the
atients with left main coronary artery PCI (n  30) as
ompared with MACCE rates seen in patients without left
ain coronary artery disease (30% vs. 16.5%) at 1 year, with
o further events in the second year. Due to the small
umber of patients with left main coronary artery disease,
o additional subanalysis was done.
econdary end points. The breakdown of MACCE events
re listed in Table 6. During the 2-year follow-up, 7 of 15
atients died because of cardiac-related disease; the others
ied of pneumonia or malignancies. Late thrombosis oc-
Figure 1. Lesion Localization
Localization of the lesions treated with TAXUS stents in multivessel coro-
nary artery disease. LAD  left anterior descending coronary artery; LCx 
left circumﬂex artery; LM  left main artery; RCA  right coronary artery.
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723urred in only 2 patients, leading to AMI followed by acute
LR.
The in-stent, proximal, and distal in-lesion late lumen
oss data are reported in Table 4. Isolated (without in-stent)
dge peri-stent restenosis was seen in 1.6% of lesions, with
imilar proportions in the proximal and distal stent edges.
e novo stenosis was documented in 21 patients (4.8%).
atients with/without off-label use for 1 lesion had a
-year MACCE of 18.7% versus 16.5% (p  0.748) and
LR of 13.5% versus 11.5% (p  0.858), respectively.
Major bleeding occurred in 3 patients during the in-
ospital phase (retroperitoneal hematoma and local femoral
ccess bleeding), and in 2 patients (intracranial bleeding
eading to death) within 1 and 6 months post-procedure.
Table 4. Quantitative Angiographic Results (n  1,080 Lesions)
Pre-stenting (n  1,080 lesions)
MLD (mm) 0.69 0.37
RD (mm) 2.61 0.64
%DS (%) 73.3 12.8
Post-stenting (n  1,080 lesions)
MLD (mm) 2.23 0.44
RD (mm) 2.63 0.97
%DS (%) 11.9 8.3
Follow-up (n  832 lesions)
In-stent
MLD (mm) 2.03 0.67
RD (mm) 2.65 0.62
%DS (%) 21.5 21.8
In-lesion proximal
MLD (mm) 2.33 0.77
RD (mm) 2.81 0.57
%DS (%) 16.33 20.6
In-lesion distal
MLD (mm) 1.93 0.62
RD (mm) 2.31 0.53
%DS (%) 15.8 18.5
In-stent late lumen loss (mm) 0.19 0.63
Proximal in-lesion late lumen loss (mm) 0.1 074
Distal in-lesion late lumen loss (mm) 0.29 0.58
Binary restenosis rate 10.8%
MLDminimal lumen diameter; RD reference diameter; %DS percent diameter stenosis.
Table 5. Clinical 2-Year Follow-Up Events With MACCE*
First 30 days, complications 15 (3.4%)
Cumulative 6-month MACCE 47 (10.2%)
Cumulative 1-yr MACCE 66 (15.7%)
Cumulative 2-yr MACCE 78 (18.3%)
All-cause death and/or acute myocardial
infarction at 1 yr
20 (4.8%)
All-cause death and/or acute myocardial
infarction at 2 yrs
22 (5.3%)
*Kaplan-Meier estimates considering also the censored data.
MACCE  major adverse cardiac and cerebrovascular events (death, nonfatal myocardialrinfarction, target vessel revascularization, cerebrovascular events).redictors of MACCE. In the multivariate Cox regression
odel (Fig. 2), the significant predictors of 2-year MACCE
ere age (hazard ratio [HR]: 1.03, p  0.019) and UA/
STEMI (HR: 2.10, p  0.001). Diabetes mellitus (HR:
.50, p  0.081) was close to significant in prediction of
ACCE. Previous PCI/CABG and incomplete revascu-
arization exhibited a time dependence for prediction of
ACCE. The different clinical outcomes of subgroups of
atients (UA/NSTEMI at clinical presentation, age 70
ears, diabetes mellitus, and previous PCI/CABG) are
llustrated by Kaplan-Meier estimates of MACCE-free
urvival (Figs. 3 and 4).
When all-cause mortality was chosen as a dependent
ariable, the Cox model identified UA/NSTEMI (HR:
.28, 95% CI: 1.18 to 9.78, p  0.024) and incomplete
evascularization (HR: 3.71, 95% CI: 1.30 to 10.34, p 
.011) as significant variables. Mortality and/or AMI was
redicted significantly by incomplete revascularization (HR:
.84, 95% CI: 1.60 to 9.11, p  0.002) and UA/NSTEMI
HR: 2.40, 95% CI: 1.01 to 5.75, p  0.046) (Fig. 5).
atients with incomplete revascularization already had a
igher composite of death or AMI (9.1% vs. 1.42%, p 
.001) in the in-hospital phase (Fig. 5). Additional analysis
Table 6. Breakdown of Clinical Follow-Up Events
At 30 days (n  441)
Procedural complications 3.6%
Acute stent thrombosis 0.7%
Subacute stent thrombosis 0.5%
Major bleeding 1.4%
Prolonged hospital stay of noncardiac reason 3.2%
Myocardial infarction 0.9%
Target lesion revascularization 0.5%
Death 2.0%
Cardiac death 1.1%
At 6 months (n  441)
Myocardial infarction 1.1%
Target lesion revascularization 6.1%
Death 2.7%
Stroke 0.2%
At 1 yr (n  418)
Myocardial infarction 1.4%
Target lesion revascularization 11.0%
Death 3.1%
Stroke 0.2%
At 2 yrs (n  407)
Late thrombosis 0.5%
Myocardial infarction 1.4%
Target lesion revascularization 13.1%
Death 3.6%
Cardiac death 1.7%
Stroke 0.2%evealed that chronic total occlusion did not predict incom-
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724lete revascularization (odds ratio: 0.572, 95% CI: 0.249 to
.317, p  0.184).
YNTAX score. The median of the cumulative SYNTAX
core was 23.0 (range 12 to 56.5, with quartiles of 19.0 and
9.0). No scores were applicable for bypass vessels or
estenotic lesions or for vessels with previously successful
oronary procedure. Furthermore, the SYNTAX score of a
ight coronary artery lesion seemed to be underscored (basic
core of 1 as compared with a basic score of 2.5 of the
roximal left circumflex artery if left dominance and of 3.5
f the proximal left anterior descending coronary artery)
ven though a right dominance of coronary circulation was
ound in 358 patients (81.2%).
Patients with/without MACCE or TLR during the 2-year
ollow-up had similar initial SYNTAX scores of 22.0 (19.0 to
0.0) versus 23.0 (19.0 to 28.0) (p  0.26) for MACCE and
3.0 (19.0 to 28) versus 22.0 (19.0 to 31.5) (p  0.206) for
LR. Receiver-operator characteristic analysis revealed low
redictive accuracies of 0.518 (p  0.206) and of 0.510 (p 
.205), with no clear cutoff value being predictive for occur-
ence of TLR or MACCE, respectively. Patients with SYN-
AX score values within the second quartiles (values between
9 and 23) had similarly poor outcomes as did patients with the
ighest scores of 29.0 (MACCE rates of 18.9%, 24.7%,
.4%, and 22.2%, p 0.04 for SYNTAX score19, 19 to 23,
23 to 28, and 29, respectively). Further subanalysis re-
ealed that 18 of the 19 patients with right coronary artery
LR had a cumulative score in the second quartile range
Figure 2. Predictors of MACCE
Hazard ratio with 95% conﬁdence intervals (CIs) up to 2-year major adverse ca
CABG  coronary artery bypass grafting; PCI  percutaneous coronary interve
myocardial infarction.between 19 and 23). (iscussion
he major findings of our evaluation of the outcome of
atients after multivessel TAXUS implantation are the low
ACCE rates at 30 days, 6 months, and 1 and 2 years,
hich are comparable to, or even better than, the results of
ther studies in which the outcome of multivessel PCI was
ssessed. As expected, the MACCE rate was mainly driven
y a 13.1% need for TLR. The binary restenosis rate of
0.8% reflected a positive selection bias (all patients with
linical symptoms were controlled angiographically), but
as paralleled by an excellent in-stent and in-lesion late
umen loss.
omparison with the SYNTAX study. In contrast with the
UTAX registry (included patients with possibly complete
evascularization with multivessel PCI), the aim of the SYN-
AX trial was to investigate the noninferiority of multivessel
CI with DES to CABG. Besides the exclusion of patients
ith post-PCI lesions in the SYNTAX study, there are other
mportant differences between the SYNTAX and AUTAX
rials: the patients included in the AUTAX registry less
requently exhibited left main, bifurcation, or trifurcation lesion
nd 3-vessel disease (33.5%, 72.4%, 10.7%, and 65.4%, respec-
ively, in the SYNTAX study PCI randomized group). The
atients in the SYNTAX study PCI arm had more treated
esions (mean 3.6), longer stented segments (mean 86.1 mm),
nd more frequent total occlusion (24.2%) than the AUTAX
tudy patients, with a consequently higher SYNTAX score
and cerebrovascular events (MACCE) (Cox proportional hazard model).
revasc.  revascularization; UA/NSTEMI  unstable angina/non–ST-segmentrdiac
ntion;28.4  11.5) (14). Therefore, the AUTAX registry popula-
t
S
i
m
N
w
a
i
s
f
S
t
b
p
S
M
w
m
T
r
c
p
t
r
C
m
J
(
u
2
O
t
t
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 8 , 2 0 0 9 Gyöngyösi et al.
A U G U S T 2 0 0 9 : 7 1 8 – 2 7 2-Year Results of the AUTAX Registry
725ion represents a lower risk profile as compared with the
YNTAX study patients, which could also explain the lower
ncidence of events. In contrast, the AUTAX study patients
ore frequently demonstrated small vessel disease and UA/
STEMI. Additionally, 78% of the AUTAX study patients
ere controlled angiographically, even if the high frequency of
ngiographic follow-up might contrarily contribute to the high
ncidence of nonclinically driven revascularization, especially in
ome patient groups (e.g., left main disease). The 2-year
ollow-up period (in contrast with the 1-year follow-up in the
YNTAX study) yielded additional important information on
he occurrence of MACCE, as concerns have recently also
een raised about the higher late stent thrombosis rate in
atients with multivessel disease treated with DES (18).
In spite of the differences between the patients in the
YNTAX and AUTAX trials, the 1-year cumulative
ACCE rates and the rates of TLR, death, and stroke
Figure 3. Cumulative MACCE-Free Survival in Patients With/Without
UA/NSTEMI and Age >70 yrs
(A) MACCE-free survival in UA/NSTEMI. Two-year survival Kaplan-Meier esti-
mates of MACCE-free survival in patients with UA/NSTEMI or stable angina
(SA). (B) MACCE-free survival age 70 years. Two-year survival Kaplan-Meier
estimates of MACCE-free survival in patients age 70 years. Probability values
are calculated with log-rank tests at the time points of clinical controls. Abbre-
viations as in Figure 2.ere similar. However, less stent thrombosis (1.2%) and lessyocardial infarction (0.9%) were documented in the AU-
AX registry (3.3% and 4.8% in the SYNTAX study PCI
andomized arm), suggesting the possible preventive role of
ontrol angiography in multivessel CAD.
The SYNTAX PCI only registry arm included inoperable
atients (with de novo lesions), and this patient cohort is
herefore not comparable with the cohort in the AUTAX
egistry.
ypher stent in multivessel CAD. After the treatment of
ultivessel CAD with sirolimus-eluting stents (Cordis, a
ohnson&Johnson, Bridgewater, New Jersey), Orlic et al.
6) reported a MACE rate of 22.3% at 6.5 months in
nselected lesions, which is higher than our 1-year and
-year MACCE rates. The earlier recruiting period of the
rlic et al. (6) study may suggest an improved procedural
echnique and optimized use of dual antiplatelet therapy at
he time of the AUTAX registry.
Figure 4. Cumulative MACCE-Free Survival in Patients With/Without
DM and Previous PCI
(A) MACCE-free survival in diabetes mellitus (DM). Two-year survival
Kaplan-Meier estimates of MACCE-free survival in patients with or without
DM. (B) MACCE-free survival in post-PCI patients. Two-year survival Kaplan-
Meier estimates of MACCE-free survival in patients with PCI. Probability val-
ues are calculated with log-rank tests at the time points of clinical controls.
Abbreviations as in Figure 2.
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726utcomes of PCI and CABG in multivessel CAD. Recent
tudies have reported an absolute benefit of CABG in mul-
ivessel CAD, with significantly lower rates of death, AMI,
nd composite MACE as compared with multivessel treat-
ent with DES (9,19), due to off-pump surgery or use of
rterialgrafts (20).However, theARTS-II (ArterialRevascular-
zation Therapies Study Part II: Sirolimus-Eluting Stents for
he Treatment of Patients With Multivessel De Novo Coro-
ary Artery Lesions) (21) and SYNTAX trials reported similar
ates of death and AMI for both PCI and CABG, with a
ignificantly higher rate of TLR but less stroke in the PCI arm.
Even if CABG is traditionally favored over PCI, the repeat
evascularization rate is poorly reported at the time frames (5 to
0 years) at which CABG graft degeneration occurs. Relative
enefits of PCI are the improved recovery and reduced neu-
Figure 5. Cumulative AMI and/or Death-Free Survival in Patients With/
Without UA/NSTEMI and Incomplete Revascularization
(A) Death or acute myocardial infarction (AMI)-free survival in UA/NSTEMI.
Two-year survival Kaplan-Meier estimates of death or AMI-free survival in
patients with UA/NSTEMI or SA. (B) Death or AMI-free survival in complete
revascularization (R). Two-year survival Kaplan-Meier estimates of death or AMI-
free survival in complete R versus incomplete R. Probability values are calcu-
lated with log-rank tests at the time points of clinical controls. Abbreviations as
in Figures 2 and 3.ologic complications (e.g., stroke and the less often reported tubtle neurocognitive dysfunction). In addition, the virtually
igher morbidity of CABG (e.g., sternal wound infection or
eg infection from harvesting, ventilator pneumonia, early graft
losure, pericarditis, or atrial fibrillation) also favors PCI. The
ospital stay and the neurologic complications were similarly
ow in the AUTAX and SYNTAX trials, and the number of
atients with prolonged hospital stay for noncardiac reasons
as also very low.
Although less invasive (and thus preferred by patients), PCI
ay not provide complete revascularization. In our study,
ncomplete revascularization predicted mortality and the com-
ined end point of death or myocardial infarction. Similar to
ur findings, Hannan et al. (22) reported that stent patients
ith incompletely revascularized multivessel CAD were sig-
ificantly more likely to die at any time than completely
evascularized patients. Interestingly, Alamanni et al. (23)
nvestigated the impact of completeness of coronary revascu-
arization on long-term outcomes after on- or off-pump
ABG, and reported that both incomplete revascularization
nd increasing numbers of distal anastomoses (even when
ontrolling for completeness of revascularization) were signif-
cant predictors of perioperative myocardial infarction. Com-
lete revascularization could be achieved in 63.2% to 74.7% of
he SYNTAX CABG randomized arm and registry and 56.7%
o 36.5% of the PCI randomized arm and registry, which was
ot reported to be in association with increased event rate. In
ur study, incomplete revascularization was a result of diverse
auses not predictable before procedure, and was likewise not
redicted by chronic total occlusion, and the unfavorable
rocedural outcome did not merit the indication for emergency
r elective bypass surgery. In contrast with the reported studies
e.g., 69% by Hannan et al. [22] or the SYNTAX study), the
ate of complete revascularization in the AUTAX trial was
uch higher (90.5%), which mirrors the striving for achieve-
ent of the complete restoration of myocardial perfusion in a
ercutaneous way, if possible.
In recent clinical practice, DES are also implanted for
esions with off-label indications, which may be at higher risk
f subsequent cardiac events. However, current data suggest
hat the use of DES in most lesion subsets is at least as safe as
are-metal stent use and clearly more efficacious than the use of
are-metal stents (24). Almost 60% of our patients had 2
esions, and additionally 21% of patients had 1 lesion with an
ff-label indication, with a diverse combination of lesion
ubsets. In comparison with other studies involving “off-label”
ES implantation, the rates of TLR and MACCE events
ere similar in our study (25).
In contrast with the randomized or observational TAXUS
tudies including de novo native lesions, the AUTAX registry
lso included patients with small vessel disease (32.7%), with
n expected lower late lumen loss. Further, we analyzed the
roximal and distal reference segments separately, which again
esults in some differences between the AUTAX and other
rials as regards the quantitative angiographic data.
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727Even if the number of events (78 events) was low for the
umber of predictors (10 predictors) in multivariate ap-
roach, we investigated the known predictive factors for
ccurrence of MACCE and death or AMI.
he SYNTAX score. Interestingly, the SYNTAX score in our
opulation did not predict worse outcome, probably for
everal reasons, including underscoring of right coronary
rtery lesions in right coronary dominance, lack of scoring of
ypass vessels or restenotic lesions, and vessels with previous
oronary procedures. In the real-world setting, increasing
umbers of patients are repeatedly treated with PCI, with
n apparently higher risk of restenosis and consequent
evascularization, which should be considered in the SYN-
AX score system. Almost half of our patients had previous
CI or CABG; exclusion of these patients from the scoring
ystem would have led to a severe bias.
onclusions
ith the aim of complete revascularization, multiple
AXUS stent implantation is safe for patients with mul-
ivessel CAD, with low incidence of late stent thrombosis,
ven with off-label indications or complex coronary anatomy
nfavorable for bypass surgery.
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